Yule, Michael S.; Thompson, Joshua; Leesahatsawat, Khachonphat; Sousa, Mariana S.; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Dajani, Olav; Fallon, Marie; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; McDonald, James; McGovern, Josh; Roeland, Eric J.; Sayers, Judith; Skipworth, Richard J.E.; Ottestad, Inger; Philips, Iain; Simpson, Melanie Rae; Solheim, Tora S; Vagnildhaug, Ola Magne; McMillan, Donald; Laird, Barry J; Dolan, Ross D. (Peer reviewed; Journal article, 2024)
Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve
drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement ...